These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 24104553)
1. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Ni F; Zhao H; Cui H; Wu Z; Chen L; Hu Z; Guo C; Liu Y; Chen Z; Wang X; Chen D; Wei H; Wang S Cancer Lett; 2015 Jan; 356(2 Pt B):809-18. PubMed ID: 25449782 [TBL] [Abstract][Full Text] [Related]
3. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933 [TBL] [Abstract][Full Text] [Related]
4. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β. Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840 [TBL] [Abstract][Full Text] [Related]
5. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381 [TBL] [Abstract][Full Text] [Related]
6. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061 [TBL] [Abstract][Full Text] [Related]
7. miR-922 regulates CYLD expression and promotes the cell proliferation of human hepatocellular carcinoma. Liu J; Su Z; Zeng Y; Zhang H; Yang S; Liu G Oncol Rep; 2017 Mar; 37(3):1445-1450. PubMed ID: 28184924 [TBL] [Abstract][Full Text] [Related]
8. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Hellerbrand C; Bumes E; Bataille F; Dietmaier W; Massoumi R; Bosserhoff AK Carcinogenesis; 2007 Jan; 28(1):21-7. PubMed ID: 16774947 [TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 promotes the cell growth and invasive ability of hepatocellular carcinoma cells by upregulating c-Myc expression via EP4 receptor and the PKA signaling pathway. Xia S; Ma J; Bai X; Zhang H; Cheng S; Zhang M; Zhang L; Du M; Wang Y; Li H; Rong R; Shi F; Yang Q; Leng J Oncol Rep; 2014 Oct; 32(4):1521-30. PubMed ID: 25109834 [TBL] [Abstract][Full Text] [Related]
10. Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway. Zhe Y; Li Y; Liu D; Su DM; Liu JG; Li HY Tumour Biol; 2016 Oct; 37(10):13951-13959. PubMed ID: 27492456 [TBL] [Abstract][Full Text] [Related]
11. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Wu YM; Liu CH; Huang MJ; Lai HS; Lee PH; Hu RH; Huang MC Cancer Res; 2013 Sep; 73(17):5580-90. PubMed ID: 23832667 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Shen G; Rong X; Zhao J; Yang X; Li H; Jiang H; Zhou Q; Ji T; Huang S; Zhang J; Jia H Carcinogenesis; 2014 Dec; 35(12):2748-55. PubMed ID: 25280563 [TBL] [Abstract][Full Text] [Related]
13. MiR-501-5p regulates CYLD expression and promotes cell proliferation in human hepatocellular carcinoma. Huang DH; Wang GY; Zhang JW; Li Y; Zeng XC; Jiang N Jpn J Clin Oncol; 2015 Aug; 45(8):738-44. PubMed ID: 25917358 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Lee EK; Kim HJ; Lee KJ; Lee HJ; Lee JS; Kim DG; Hong SW; Yoon Y; Kim JS Int J Oncol; 2011 Feb; 38(2):325-33. PubMed ID: 21132267 [TBL] [Abstract][Full Text] [Related]
16. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853 [TBL] [Abstract][Full Text] [Related]
17. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells. Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018 [TBL] [Abstract][Full Text] [Related]
18. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. Hayashi M; Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Yamada S; Fujii T; Sugimoto H; Takeda S; Kodera Y J Surg Oncol; 2012 Mar; 105(4):381-6. PubMed ID: 22052684 [TBL] [Abstract][Full Text] [Related]
19. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167 [TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Qiyong L; Fujii T; Sugimoto H; Takeda S; Nakao A Ann Surg Oncol; 2010 Mar; 17(3):923-32. PubMed ID: 19898900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]